Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: A randomized, double-blind, controlled, prospective study

Journal of Clinical Psychiatry

Volumn 68, Issue 11, 2007, Pages 1793-1798

  Saddichha, Sahoo ^a   Manjunatha, Narayana ^a   Ameen, Shahul ^b   Akhtar, Sayeed ^a  

^a CENTRAL INSTITUTE OF PSYCHIATRY   (India)

^b ST JOHN'S HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT; WEIGHT GAIN;

EID: 37049014240     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1120     Document Type: Article

References (42)

1. Arterburn D, Noel PH. Obesity. BMJ 2001;322:1406-1409
2. Bajaj JS. Cellular and molecular biology of adiposity and adipogenesis. Gupta SB, ed. Medicine Update. Mumbai, India: Association of Physicians of India 2002;12:457-466
3. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Eng J Med 1990;322:882-889
4. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19:16-27
5. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
6. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62:22-31
7. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149:689-690
8. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55:157-160
9. Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry 1998;43:520-524
10. Brixner DI, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006;40:626-632
11. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58:45-49
12. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57:53-60
13. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(suppl 10):13-17
14. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134
15. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305
16. Owens DG. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55:29-35
17. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
18. Kuan-Pin Su, Po-Lun Wu, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology 2005;183:383-386
19. Theleritis CG, Papadimitriou GN, Papageorgiou CC, et al. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. BMC Psychiatry 2006;6:37
20. Sahoo S, Mishra B, Akhtar S. Dose dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report. Br J Clin Pharmacol 2007 May 17 [Epub ahead of print]
21. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79-87
22. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100
23. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
24. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004;47:S76-S79
25. Brugha TS, Wing JK, Smith BL. Physical health of the long-term mentally ill in the community: is there unmet need? Br J Psychiatry 1989;155:777-781
26. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996;169:733-739
27. Thakore J, Mann J, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-141
28. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl 2004;47:S102-S105
29. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28:995-1003
30. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62
31. Novick D, Haro JM, Belger M, et al. Clinical and tolerability status of previously untreated schizophrenic patients over the first 24 months of treatment: results from the Schizophrenia Outpatient Health Outcomes (SOHO) Study [poster]. Presented at the International Congress on Schizophrenia Research (ICOSR); April 2-6, 2005; Savannah, Ga
32. Methods in Human Nutritional Assessment. Estimating daily energy requirements. Available at: http://people.brandeis.edu/~rgodoy/NSfTraining/ Fieldmethods-diet&activity-2005.pdf. Accessibility verified October 3, 2007
33. WHO Expert Consultation. Appropriate body mass index for Asian population and its implications for policy and interventional strategies. Lancet 2004;363:157-163
34. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects, 2000. Available at: http://www.wma.net. Accessibility verified October 3, 2007
35. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-28
36. Druss BG, Bradford DW, Rosenheck RA, et al. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000;283:506-511
37. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003;59:19-27
38. Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults. Diabetes Care 2003;26:1380-1384
39. European Federation of Associations of Families of Mentally Ill People, 2001. Available at: http://www.eufami.org. Accessibility verified October 3, 2007
40. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among patients with schizophrenia. Psychiatr Serv 2003;54:565-567
41. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999;341:1097-1105
42. Corey-Lisle PK, Kolotkin RL, Crosby RD, et al. Schizophrenia: relationship between body mass index and quality of life. Abstract presented at the annual meeting of the American Psychiatric Association; 2005; Atlanta, Ga. Available at: http://www.psych.org/public_info/libr_publ/abstracts.cfm. Accessed May 12, 2006